Due to the high mortality rate of COVID-19, the assessment of BNT162b2 SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech) efficacy in allogeneic hematopoietic stem cell transplant (HSCT) recipients is mandatory.
Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation
Barabino, L
;Galitzia, A;Caocci, G;Greco, M;Mulas, O;Costa, A;La Nasa, GUltimo
2022-01-01
Abstract
Due to the high mortality rate of COVID-19, the assessment of BNT162b2 SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech) efficacy in allogeneic hematopoietic stem cell transplant (HSCT) recipients is mandatory.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
8984-8989-1.pdf
accesso aperto
Tipologia:
versione post-print (AAM)
Dimensione
463.14 kB
Formato
Adobe PDF
|
463.14 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
